Singer Watson begins radiotherapy

Singer Russell Watson has started an intensive five-week course of radiotherapy at a Manchester hospital to treat a recurrent brain tumour.

The 41-year-old performer, who will undergo the treatment for five days each week, said he was "a little bit tired" and it was a "strange New Year".

Watson's manager Richard Thompson said doctors were being cautious not to damage his eyesight with the therapy.

The singer underwent emergency brain surgery in October.

'Arduous'

Mr Thompson added: "He's got five days a week for five weeks to really whack the thing completely in the hope that it will never regrow.

"It's a very arduous five-week period that the doctors hope will give him closure," he said, indicating that hair loss and fatigue could also result from the treatment at the Christie Hospital.

"He's in as good as spirits as anybody can be with that kind of journey ahead."

Watson's tumour is located close to the optic nerve, which has prompted caution about his eyesight.

Speaking last month, the singer said that he would not be singing for some time, but expected his voice to recover from surgery which was performed via his mouth.

He had his first operation in 2006 to remove the tumour, but later scans revealed that it had grown back before emergency surgery last year.
This is a part of article Singer Watson begins radiotherapy Taken from "Buy Propecia Finasteride" Information Blog

Cost Studies in Rheumatology, 2001-2002

Cost Studies in Rheumatology, 2001-2002

from Current Opinion in Rheumatology

Management of Infected Total Joint Replacement

Fisman et al.[9] performed an excellent study examining the cost-effectiveness of two-stage exchange arthroplasty and open debridement with prosthesis retention in elderly patients with infected total hip arthroplasty. Lifetime direct medical costs as well as indirect costs from loss of productivity were assessed using a Markov model. Incremental ratios demonstrated that when compared with exchange arthroplasty, initial debridement and retention had lower cost-effectiveness ratios ($500-$21,800/QALY) in all cohorts regardless of gender.

This is a part of article Cost Studies in Rheumatology, 2001-2002 Taken from "Leflunomide Arava 20Mg" Information Blog

Prostate Cancer: Screening and Early Detection

Prostate Cancer: Screening and Early Detection

from Cancer Control: Journal of the Moffitt Cancer Center

Results of Early Detection

There is overwhelming evidence that the widespread use of PSA has resulted in the improvement of detection of prostate cancer at an earlier stage. In published data[11] based on results of annual Prostate Cancer Awareness Week, serial screening for prostate cancer significantly improved the rate of early cancer detection. In the SEER database, the rate of distant metastases fell more than 50% between 1990-1994, a finding thought to be largely attributable to PSA use.[25] Furthermore, in data comparing radical prostatectomy specimens from the pre-PSA era with those in the last decade, tumors in 70%-80% of men are now being detected while the tumors are still pathologically organ confined compared with less than 30% prior to the use of PSA.[26] These findings have raised criticism that many of these PSA-detected tumors are clinically insignificant, but in fact that does not appear to the case. Recent pathology evidence from men with PSA detected tumors reveal that less than 10%-15% of all prostatectomy specimens contain what might be considered clinically insignificant tumors similar to those found at the time of autopsy.[27] However, PSA detection alone may be inadequate if not performed as part of an early detection program, as evidenced by the large number of tumors with microscopic extraprostatic extension (up to 50% in some series) despite lack of tumor palpability.[28]

This is a part of article Prostate Cancer: Screening and Early Detection Taken from "Buy Propecia Finasteride" Information Blog